Dexcom appoints Jacob S.
Filed with the SEC on · Summarized by InvestorsBot
Dexcom appoints Jacob S. Leach as President & CEO and director effective Jan 1, 2026; he’s been interim CEO during Kevin Sayer’s medical leave. Board expects Sayer to return ~Mar 2026; Mark Foletta remains interim Chair. $DXCM 👨💼 #CEO #CorporateGovernance
Offer letter (Dec 19, 2025): Leach base salary $1,150,000; target bonus 150% of base; RSUs with $7.5M fair value vesting annually over 3 yrs; PSUs target $7.5M subject to performance; eligible for exec severance & employee benefits. $DXCM 💰 #Compensation
Biographical details filed in Dexcom’s Schedule 14A (Mar 27, 2025). Company states no related-party arrangements, no family ties, and no material transactions requiring Item 404 disclosure tied to Leach’s appointment. $DXCM 🧾 #CorporateGovernance #SEC